View Item 

Show simple item record

A Model of Methotrexate Encephalopathy: Neurotransmitter and Pathologic Abnormalities
dc.contributor.authorSilverstein, Faye Sarahen_US
dc.contributor.authorJohnston, Michael V.en_US
dc.date.accessioned2010-04-13T19:22:05Z
dc.date.available2010-04-13T19:22:05Z
dc.date.issued1986en_US
dc.identifier.citationSilverstein, Faye; Johnston, Michael (1986). "A Model of Methotrexate Encephalopathy: Neurotransmitter and Pathologic Abnormalities." Journal of Child Neurology 1(4): 351-357. <http://hdl.handle.net/2027.42/67332>en_US
dc.identifier.issn0883-0738en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/67332
dc.description.abstractMethotrexate may cause seizures, dementia, and leukoencephalopathy when given in toxic doses to children with leukemia or solid tumors. Even in therapeutic doses, treatment with this drug is associated with an increased incidence of seizures in children with leukemia. To study mechanisms of injury, juvenile rats were given multiple intraventricular injections of methotrexate and the brains were analyzed for histopathology and biogenic amine metabolites of dopamine and serotonin. Disruption of monoamine metabolism has been proposed as a cause of brain dysfunction from this chemotherapy. Multiple injections (1 or 2 mg/kg) produced convulsions in an increasingly larger percentage of animals at higher cumulative doses, and five doses produced the neuropathological changes seen in human leukoencephalopathy. A single dose reduced the concentration of brain metabolites of dopamine, but not serotonin, six hours later. The effect was less pronounced after five doses. This rodent model should be useful for studying the metabolic basis of methotrexate encephalopathy. (J Child Neurol 1986;1:351-357)en_US
dc.format.extent3108 bytes
dc.format.extent732993 bytes
dc.format.mimetypetext/plain
dc.format.mimetypeapplication/pdf
dc.publisherSage Publicationsen_US
dc.titleA Model of Methotrexate Encephalopathy: Neurotransmitter and Pathologic Abnormalitiesen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartments of Pediatrics and Neurology, the University of Michigan Medical Center, Ann Arbor, MIen_US
dc.contributor.affiliationumDepartments of Pediatrics and Neurology, the University of Michigan Medical Center, Ann Arbor, MIen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/67332/2/10.1177_088307388600100406.pdf
dc.identifier.doi10.1177/088307388600100406en_US
dc.identifier.sourceJournal of Child Neurologyen_US
dc.identifier.citedreferenceBleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981;65:89-97.en_US
dc.identifier.citedreferenceAllen JC: The effects of cancer therapy on the nervous system. J Pediatr 1978;93:903-909.en_US
dc.identifier.citedreferenceKay HEM, Knopton PJ, O'Sullivan JP, et al: Encephalopathy in acute leukemia associated with methotrexate therapy. Arch Dis Child 1972;47:344-354.en_US
dc.identifier.citedreferencePizzo PA, Poplack DG, Bleyer WA: Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1979;1:127-140.en_US
dc.identifier.citedreferenceKaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Semin Oncol 1982;9:103-125.en_US
dc.identifier.citedreferenceHara T., Kishikawa T., Miyazaki S., et al: Central nervous system complications in childhood leukemia. Am J Pediatr Hematol Oncol 1984;6:129-136.en_US
dc.identifier.citedreferenceEttinger LJ: Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982;50:444-450.en_US
dc.identifier.citedreferencePoplack DG: Massive intrathecal overdose: "Check the label twice!" N Engl J Med 1984;311:400-401.en_US
dc.identifier.citedreferencePizzo PA, Bleyer WA, Poplack DG, Leventhal BG: Reversible dementia temporally associated with intraventricular therapy with methotrexate in a child with acute myelogenous leukemia. J Pediatr 1976;88:131-133.en_US
dc.identifier.citedreferenceCh'ien LT, Aur RJA, Stagner S., et al: Long term neurological implication of somnolence syndrome in children with acute lymphocytic leukemia. Ann Neurol 1980;8:273-277.en_US
dc.identifier.citedreferenceAllen JC, Rosen G.: Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma. Ann Neurol 1978;3:441-444.en_US
dc.identifier.citedreferencePfefferbaum-Levine B., Copeland DR, Fletcher JM, et al: Neuropsychological assessment of long term survivors of childhood leukemia. Am J Pediatr Hematol Oncol 1984;6:123-128.en_US
dc.identifier.citedreferenceMc Intosh S., Klatskin EH, O'Brien RT, et al: Chronic neurologic disturbance in childhood leukemia. Cancer 1976;37:853-857.en_US
dc.identifier.citedreferencePavlovsky S., Castano J., Leiiguarda R., et al: Neuropsychological study in patients with ALL. Am J Pediatr Hematol Oncol 1983;5: 79-86.en_US
dc.identifier.citedreferenceOchs JO, Pui C., Mason C.: Seizures in childhood lymphoblastic leukemia patients. Lancet 1984;2:1422-1424.en_US
dc.identifier.citedreferencePeylan-Rarnu M., Poplack DG, Pizzo PA: Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 1978;298:815-818.en_US
dc.identifier.citedreferenceClausen N., Pederson H.: Cranial computed tomography during treatment of childhood lymphocytic leukemia. Acta Pediatr Scand 1982;71:257-262.en_US
dc.identifier.citedreferenceHendin B., Devivo D., Torack R., et al: Parenchymatous degeneration of the central nervous system in childhood leukemia. Cancer 1974;33:468-482.en_US
dc.identifier.citedreferenceSmith B.: Brain damage after intrathecal methotrexate. J Neurol Neurosurg Psychiatr 1975;38:810-815.en_US
dc.identifier.citedreferencePrice RA, Jamieson PA: The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 1975; 35:306-318.en_US
dc.identifier.citedreferenceRubenstein LJ, Hermon MM, Long TF, Wilbur JR: Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975 ; 35:291-305.en_US
dc.identifier.citedreferenceDe Vivo DC, Malas D., Nelson JS, Land VJ: Leukoencephalopathy in childhood leukemia. Neurology 1977;27:609-613.en_US
dc.identifier.citedreferenceCrosley CJ, Rorke LB, Evans A., Nigro M.: Central nervous system lesions in childhood leukemia. Neurology 1978;28:678-685.en_US
dc.identifier.citedreferenceJolivet J., Cowan KH, Curt GA, et al: The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-1103.en_US
dc.identifier.citedreferenceAbelson HT: Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978;62:1999-2001.en_US
dc.identifier.citedreferenceJohnston MV, Singer HS: Brain neurotransmitters and neuro-modulators in pediatrics. Pediatr 1982;70:57-68.en_US
dc.identifier.citedreferenceInglis JK: Introduction to Laboratory Animal Science and Technology. Oxford, Pergamon Press, 1980.en_US
dc.identifier.citedreferenceSilverstein F., Johnston M.: Effects of hypoxia-ischemia on monoamine metabolism in the immature brain. Ann Neurol 1984;15: 342-347.en_US
dc.identifier.citedreferenceOlney JW, Fuller TA, Gubareff T.: Kainate-like neurotoxicity of folates. Nature 1981;292:165-167.en_US
dc.identifier.citedreferencePrice RA, Birdwell DA: The central nervous system in childhood leukemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 1978;42:717-728.en_US
dc.identifier.citedreferenceShapiro WR, Allen JC, Horten BD: Chronic methotrexate toxicity to the central nervous system. Sloan-Kettering Memorial Hospital Clinical Bulletin 1980;10:49-52.en_US
dc.identifier.citedreferenceBleyer WA, Dedrick RL: Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 1977;61:703-708.en_US
dc.identifier.citedreferenceBleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-773.en_US
dc.identifier.citedreferenceJohnston MV, Silverstein FS, Greenberg HS, et al: Intraventricular methotrexate alters cerebrospinal fluid homovanillic acid levels in rhesus monkeys. Neurology 1983;33(suppl 2):109.en_US
dc.identifier.citedreferenceLevine RA, Miller LP, Lovenberg W.: Tetrahydrobiopterin in striatum: Localization in dopamine nerve terminals and role in catecholamine synthesis. Science 1981;214:919-921.en_US
dc.identifier.citedreferencePollock RJ, Kaufman S.: Dihydrofolate reductase is present in brain. J Neurochem 1977;30:253-256.en_US
dc.identifier.citedreferenceCulvenor AJ, Miller LP, Levine RA, Lovenberg W.: Effects of methotrexate on biopterin levels and synthesis in rat cultured pineal glands. J Neurochem 1984;42:1707-1714.en_US
dc.identifier.citedreferenceLiang BT, Vaccaro KK, Perelle BA, Perlman RL: Studies on dihydropteridine reductase activity in pheochromocytoma cells. J Neurochem 1981;37:1164-1169.en_US
dc.identifier.citedreferenceKoslow SH, Butler IJ: Biogenic amine synthesis defect in dihydropteridine reductase deficiency. Science 1977;198:522-523.en_US
dc.identifier.citedreferenceKaufman S., Berlow S., Summer GK, et al: Hyperphenylalaninemia due to a deficiency of biopterin. N Engl J Med 1978;299:673-679.en_US
dc.identifier.citedreferenceBrewster TG, Moskowitz MA, Kaufman S.: Dihydropteridine reductase deficiency associated with severe neurologic disease and mild hyperphenylalaninemia. Pediatr 1979;63:94-99.en_US
dc.identifier.citedreferenceShaywitz BA, Cohen DJ, Bowers MB: Cerebrospinal fluid monoamine metabolites in neurological disorders of childhood, in Wood JH (ed): Neurobiology of Cerebrospinal Fluid. New York, Plenum Publishing Corp, 1980.en_US
dc.identifier.citedreferenceSilverstein FS, Hutchinson RJ, Johnston MV: Cerebrospinal fluid biogenic amine metabolism in children during treatment for acute lymphoblastic leukemia. Pediatr Res 1986;20:285-291.en_US
dc.identifier.citedreferenceWinkelman MD, Hines JD: Cerebellar degeneration caused by high-dose cytosine arabinoside: A clinicopathological study. Ann Neurol 1983;14:520-527.en_US
dc.identifier.citedreferenceGilman AG, Goodman LS, Gilman A.: The Pharmacological Basis of Therapeutics New York, Mac Millan Inc, 1980, pp 1272-1274.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10.1177_088307388600100406.pdf
Size:
715.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.